Abstract
Objective: To explore the distribution of drug metabolic enzymes CYP2C19 genetic polymorphism in coronary heart disease (CAD) patients of Chongqing. Methods: We have done genotyping to 179 CAD patients taking clopidogrel by gene chip method, analyzed the distribution of genotype and metabotropic phenotype. Results: In this study, a total of six different CYP2C19 genotypes and three metabotropic phenotypes were detected. The frequency of the homozygous extensive metabolizer phenotype was 32.96% (59/179), the heterozygous extensive metabolizer phenotype was 53.07% (95/179) and the poor metabolizers was 13.96% (25/179). Among the CAD patients in Chongqing, there is no significant statistical difference between these CYP2C19 genotypes and reports in other studies Conclusion: The CYP2C9 gene existed genetic polymorphism in CAD patients in Chongqing, and the distributions of allele frequency and metabolic phenotype frequency are similar to other districts in China.
Highlights
The use of clopidogrel in combination with aspirin is recommended for the prevention of coronary heart disease (CAD) according to current guidelines [1]
The CYP2C19 gene polymorphisms was a key factor in clopidogrel oxidative metabolism
A total of 179 clopidogrel on-treatment CAD patients were enrolled in the study, including123 male and 66 female
Summary
The six genotypes have included the CYP2C19*1/*1, *1/*2, *1/* 3, * 2/* 2, *2/*3 and * 3/* 3. The three metabolic types have included Extensive Metabolizer (EM), Intermediate Metabolizer (IM), Poor Metabolizer (PM). There were 130 patients mutated on 681 site G>A or (and) 636 site G>A. Compared to the distribution of metabolic type in other districts, the ratio of Chongqing had no statistical difference (P>0.05, Table 3)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
